Two years out from the U.K.'s scheduled EU exit date, the life science sector is increasingly confident about its post-Brexit prospects.

Alexion Pharmaceuticals is set to lay off 7% of its staff and scrap some R&D programs to restructure its business following a tricky period.

Ex-Pfizer exec is looking for new biopharma opportunities as Intrexon spins out all its healthcare programs into a new company.

As Donald Trump is sworn into office today, we look at what the next 100 days and indeed the next four years could mean for the biopharma industry through his…

Returns on R&D among the world's largest pharma companies are still in free fall with no signs of a recovery, says Deloitte.

Let’s be honest, 2016 was a mess of year, and one that many of us will be happy to see the back of. It saw the loss of a series of beloved actors, actresses…

Motif Bio has put together a financing package to give it the money to wrap up a Phase III trial of its antibiotic iclaprim.

uniQure plans to cut projects and R&D staff to reduce costs as it strives to bring its next product to market.

Two months ago Novavax announced that its Phase III RSV F vaccine flopped fantastically, and now, with a sense of inevitability, it has announced a “corporate…